Please wait a moment . . .
In early 2020, as the COVID-19 pandemic reshaped our world, Medialis Ltd recognised the urgent need for a disease-specific quality of life (QoL) instrument for long COVID patients. This, led to the development of the PAC-19QoL. Rapid Development Timeline: We received ethical approval in October 2020 and initiated the development of the PAC-19QoL on November...
Medialis Ltd is proud to present our latest publication: “Real-world service cost’s for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis” in Current Medical Research & Opinions Real-world Evidence section Key Highlights: Innovative Use of Neutral Theory & Jandhyala Method: We leveraged these advanced methodologies to develop the nAMD Service Non-Drug...
Payors are crucial in the adoption of new medicines, especially in markets that prioritise cost-effectiveness. While HTA agencies and payors often prioritise clinical trial data, there are significant evidence gaps that these trials do not cover. Real-World Evidence (RWE) becomes crucial in this scenario, offering additional context and data to support reimbursement applications. Submitting incomplete...
In our pursuit of cost-effectiveness, are we overlooking a crucial factor? Our recent publication, “Real-world service costs for neovascular-AMD clinics in the United Kingdom: Structured literature review and scenario analysis,” featured in Current Medical Research and Opinion, highlights significant strain costs affecting nAMD clinics, often ignored in traditional cost-effectiveness analyses. In our scenario analysis, while...
Background: There is currently no standard definition of medical affairs, despite its increasing importance to the pharmaceutical industry. The evolution of medical affairs necessitated the development of a standardised definition to guide policy and practice to ensure that patients’ interests remain central amid shifts that have, in the past, created fertile ground for ethical violations....